{
  "schemaVersion" : 2,
  "registerId" : "F2012L01794",
  "instrumentNumber" : "53/2012",
  "citation" : "Statement of Principles concerning mesangial IgA glomerulonephritis No. 53 of 2012",
  "conditionName" : "mesangial IgA glomerulonephritis",
  "effectiveFrom" : "2012-09-05",
  "standardOfProof" : "Balance of Probabilities",
  "icdCodes" : [ ],
  "onsetFactors" : [ {
    "paragraph" : "6(a)",
    "text" : "having cirrhosis of the liver or chronic liver disease at the time of the\r\nclinical onset of mesangial IgA glomerulonephritis",
    "definedTerms" : [ {
      "term" : "chronic liver disease",
      "definition" : "means progressive destruction of the liver\nparenchyma resulting in abnormal liver function which has been present for at\nleast six months"
    } ]
  }, {
    "paragraph" : "6(b)",
    "text" : "having a bacterial infection in the one month before the clinical onset\r\nof mesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(c)",
    "text" : "having received a stem cell or organ transplant before the clinical onset\r\nof mesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(d)",
    "text" : "having a specified autoimmune disorder at the time of the clinical onset\r\nof mesangial IgA glomerulonephritis",
    "definedTerms" : [ {
      "term" : "a specified autoimmune disorder",
      "definition" : "means:\n(a) ankylosing spondylitis;\n(b) Behçet's disease;\n(c) coeliac disease;\n(d) inflammatory bowel disease;\n(e) psoriatic arthritis; or\n(f) reactive arthritis"
    } ]
  }, {
    "paragraph" : "6(e)",
    "text" : "being treated with a drug which is associated in the individual with:\r\n(i) the development of mesangial IgA glomerulonephritis during\r\ndrug therapy; and either\r\n(ii) the improvement of mesangial IgA glomerulonephritis within\r\nthree months of discontinuing or tapering drug therapy; or\r\n(iii) the redevelopment of mesangial IgA glomerulonephritis on\r\nrechallenge with the same drug;\r\nwhere treatment with the drug continued for at least the seven days\r\nbefore the clinical onset of mesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(f)",
    "text" : "having a malignant neoplasm at the time of the clinical onset of\r\nmesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "6(g)",
    "text" : "having cirrhosis of the liver or chronic liver disease at the time of the\r\nclinical worsening of mesangial IgA glomerulonephritis",
    "definedTerms" : [ {
      "term" : "chronic liver disease",
      "definition" : "means progressive destruction of the liver\nparenchyma resulting in abnormal liver function which has been present for at\nleast six months"
    } ]
  }, {
    "paragraph" : "6(h)",
    "text" : "having a bacterial infection in the one month before the clinical\r\nworsening of mesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(i)",
    "text" : "having received a stem cell or organ transplant before the clinical\r\nworsening of mesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(j)",
    "text" : "having a specified autoimmune disorder at the time of the clinical\r\nworsening of mesangial IgA glomerulonephritis",
    "definedTerms" : [ {
      "term" : "a specified autoimmune disorder",
      "definition" : "means:\n(a) ankylosing spondylitis;\n(b) Behçet's disease;\n(c) coeliac disease;\n(d) inflammatory bowel disease;\n(e) psoriatic arthritis; or\n(f) reactive arthritis"
    } ]
  }, {
    "paragraph" : "6(k)",
    "text" : "being treated with a drug which is associated in the individual with:\r\n(i) the worsening of mesangial IgA glomerulonephritis during drug\r\ntherapy; and either\r\n(ii) the improvement of mesangial IgA glomerulonephritis within\r\nthree months of discontinuing or tapering drug therapy; or\r\n(iii) the worsening of mesangial IgA glomerulonephritis on\r\nrechallenge with the same drug;\r\nwhere treatment with the drug continued for at least the seven days\r\nbefore the clinical worsening of mesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(l)",
    "text" : "having a malignant neoplasm at the time of the clinical worsening of\r\nmesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(m)",
    "text" : "inhaling, ingesting or having cutaneous exposure to:\r\n(i) oxygenated organic solvents;\r\n(ii) aliphatic hydrocarbon solvents; or\r\n(iii) aromatic hydrocarbon solvents;\r\nfor an average of at least two hours per week over a period of at least\r\none year within the five years before the clinical worsening of\r\nmesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(n)",
    "text" : "being obese for at least the five years before the clinical worsening of\r\nmesangial IgA glomerulonephritis",
    "definedTerms" : [ {
      "term" : "being obese",
      "definition" : "means an increase in body weight by way of fat accumulation\nwhich results in a Body Mass Index (BMI) of 30 or greater.\n2\nThe BMI = W/H and where:\nW is the person's weight in kilograms and\nH is the person's height in metres"
    } ]
  }, {
    "paragraph" : "6(o)",
    "text" : "smoking at least five pack-years of cigarettes, or the equivalent thereof\r\nin other tobacco products, in the ten years before the clinical worsening\r\nof mesangial IgA glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(p)",
    "text" : "inability to obtain appropriate clinical management for mesangial IgA\r\nglomerulonephritis",
    "definedTerms" : [ ]
  } ]
}